Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2014 1
2015 1
2018 2
2019 2
2020 4
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
Linardou H, Lampaki S, Koliou GA, Vozikis A, Boutis A, Nikolaidi A, Kontogiorgos I, Papakotoulas P, Christopoulou A, Spyratos D, Bafaloukos D, Psyrri A, Grivas A, Koumarianou A, Tsiakitzis K, Mauri D, Rigakos G, Aravantinos G, Papantoniou P, Oikonomopoulos G, Fountzilas E, Koufaki MI, Kaparelou M, Liolis E, Mountzios G, Kosmidis P, Fountzilas G, Samantas E. Linardou H, et al. Among authors: grivas a. Anticancer Res. 2023 Jun;43(6):2799-2812. doi: 10.21873/anticanres.16449. Anticancer Res. 2023. PMID: 37247889
CYP2E1 and risk of chemically mediated cancers.
Trafalis DT, Panteli ES, Grivas A, Tsigris C, Karamanakos PN. Trafalis DT, et al. Among authors: grivas a. Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):307-19. doi: 10.1517/17425250903540238. Expert Opin Drug Metab Toxicol. 2010. PMID: 20073996 Review.
Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental.
Papakotoulas P, Tsoukalas N, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C, Papatsimpas G, Papakostas P, Samelis G, Andreadis C, Aravantinos G, Ziras N, Kalofonos C, Samantas E, Souggleri M, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Tripodaki S, Bokas A, Grivas A, Timotheadou E, Bournakis E, Varthalitis I, Boukovinas I. Papakotoulas P, et al. Among authors: grivas a. Anticancer Res. 2020 Jan;40(1):305-313. doi: 10.21873/anticanres.13954. Anticancer Res. 2020. PMID: 31892581
Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence.
Christopoulou A, Ardavanis A, Papandreou C, Koumakis G, Papatsimpas G, Papakotoulas P, Tsoukalas N, Andreadis C, Samelis G, Papakostas P, Aravantinos G, Ziras N, Souggleri M, Kalofonos C, Samantas E, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Bokas A, Grivas A, Tripodaki ES, Varthalitis I, Timotheadou E, Boukovinas I. Christopoulou A, et al. Among authors: grivas a. Oncol Lett. 2022 Apr;23(4):115. doi: 10.3892/ol.2022.13235. Epub 2022 Feb 9. Oncol Lett. 2022. PMID: 35251346 Free PMC article.
Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study.
Chlapoutakis S, Georgakopoulou VE, Trakas N, Kouvelos G, Papalexis P, Damaskos C, Sklapani P, Grivas A, Gouveris P, Tryfonopoulos D, Tzovaras A, Ardavanis-Loukeris G, Grouzi E, Spandidos DA, Matsagkas M. Chlapoutakis S, et al. Among authors: grivas a. Oncol Lett. 2022 May;23(5):168. doi: 10.3892/ol.2022.13288. Epub 2022 Apr 4. Oncol Lett. 2022. PMID: 35496573 Free PMC article.
Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
Tsoukalas N, Papakotoulas P, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C, Papatsimpas G, Papakostas P, Samelis G, Andreadis C, Aravantinos G, Ziras N, Kalofonos C, Samantas E, Souggleri M, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Tripodaki ES, Bokas A, Grivas A, Timotheadou E, Bournakis E, Varthalitis I, Boukovinas I. Tsoukalas N, et al. Among authors: grivas a. Cancers (Basel). 2020 Jul 15;12(7):1907. doi: 10.3390/cancers12071907. Cancers (Basel). 2020. PMID: 32679747 Free PMC article.
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece.
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H. Mountzios G, et al. Among authors: grivas a. Lung Cancer (Auckl). 2021 Aug 30;12:93-102. doi: 10.2147/LCTT.S318007. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34512058 Free PMC article.
Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E, Assi A, Kranidioti E, Kosma A, Karakosta M, Miltiadous C, Dimitriadis GK, Grivas A, Athanasopoulos A, Lianos E, Kosmas C. Fergadis E, et al. Among authors: grivas a. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e50-e57. doi: 10.1016/j.clml.2019.11.022. Epub 2019 Dec 6. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31884151
Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; the role of plerixafor.
Kosmas C, Kranidioti E, Kosma A, Karakosta M, Miltiadous C, Grivas A, Athanasopoulos A, Lianos E. Kosmas C, et al. Among authors: grivas a. Leuk Lymphoma. 2019 Jul;60(7):1819-1822. doi: 10.1080/10428194.2018.1543879. Epub 2019 Jan 8. Leuk Lymphoma. 2019. PMID: 30618317 No abstract available.
16 results